Mer­ck-al­lied Seat­tle Ge­net­ics’ pos­i­tive up­date on its 2nd ADC may point to an ac­cel­er­at­ed dash to the FDA fin­ish line

Seat­tle Ge­net­ics and their part­ners at Astel­las and Mer­ck con­tin­ue to build a case for quick­ly ex­pand­ing the mar­ket reach of their trend­set­ting an­ti­body drug con­ju­gate en­for­tum­ab ve­dotin. Four months af­ter they rolled in­to ES­MO with solid­ly pos­i­tive da­ta in the front­line set­ting for blad­der can­cer — and just ahead of the Nectin-4 tar­get­ed drug’s ac­cel­er­at­ed ap­proval at the FDA for sec­ond-line cas­es — in­ves­ti­ga­tors are back with an up­date that sup­ports their case on dura­bil­i­ty and ef­fi­ca­cy in a front­line niche.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER